Results: A total of 12 papers, detailing 11 studies with a total of 772 participants, evaluating nine decision aids, were included within the review. PtDAs were shown to significantly increase fertility preservation knowledge and decrease decisional conflict. Overall satisfaction with decision aids was high. Currently, only two reviewed decision aids are available for cancer patients. Another tool has been integrated into a web page, and one implementation study has been completed.
| BACKGROUND
In recent years, advancements in the detection and treatment of cancer have led to improvements in rates of survival for cancer patients of reproductive age. Treatment approaches must then consider life after cancer and management of long-term treatment effects, such as infertility and interrupted family planning. Oncological treatment, such as radiation to the pelvis and brain, and chemotherapy regimens containing alkylating agents can potentially cause high levels of damage to germ cells and affect reproductive hormone production. 1 This gonadal damage may lead to higher rates of premature ovarian failure and azoospermia compared with the general population, 2 resulting in early menopause or sterility. As such, family planning is often interrupted, with lower rates of pregnancy reported in female cancer survivors, for example, compared with sibling cohorts. 3 Actual or threatened infertility in cancer patients of reproductive age is consequently a source of significant distress and may severely impact quality of life into survivorship. 4, 5 It is therefore important that cancer patients are adequately supported in ways to manage their reproductive health throughout cancer treatment.
There are a number of fertility preservation treatment approaches recommended for cancer patients, which differ in their level of recommendation. [6] [7] [8] [9] [10] [11] [12] Methods of fertility preservation for female cancer patients include oocyte and embryo cryopreservation, ovarian transportation, conservative gynaecological surgery, ovarian suppression, or cryopreservation of ovarian tissue. 13 With the increasing success of ovarian cryopreservation and transplantation techniques, this option is more recently being considered as standard practice, especially in prepubertal patients. 14, 15 Cryopreservation of spermatozoa is the only established method of fertility preservation for male patients, with cryopreservation of testicular tissue recommended only when as part of a clinical trial or experimental protocol. 10 Patient and treatment factors may influence which preservation options, if any, are most appropriate, taking into account such factors as access to services, likely prognosis, cancer type, oncological treatment protocol, and time to commence oncological treatment. 5 The decision to undertake fertility preservation is further complicated by the concurrent distressing nature of a new cancer diagnosis, the stresses of oncological treatment planning and preparation, and possible fertility treatment financial barriers, which may vary internationally depending on the model of care utilised. 16, 17 Given the complexity of the multistep decision-making process, it is important that patients are adequately supported to determine which options are best suited to their individual situation.
Despite the need for appropriate support regarding fertility preservation, provision of patient information is often not adequate. International guidelines recommend that risks to fertility and options for preservation are discussed with patients as early as possible to allow them adequate time to make fertility treatment decisions. [6] [7] [8] [9] [10] [11] [12] However, research indicates that although the majority of patients recall a fertility discussion with their health provider, 4 up to half of patients report inadequate provision of information 18 and unmet information needs. 19 Moreover, written materials are often not age appropriate for younger reproductive age cancer patients. 20 The majority of patients (up to 73%) are concerned about fertility, 21 and as such, irrespective of whether they ultimately choose to undergo fertility preservation, patients appreciate the opportunity to discuss fertility issues and deem fertility information to be important. 22, 23 Furthermore, lack of knowledge about fertility issues is correlated with greater levels of decisional conflict and regret, which can lead to long-term psychological impacts in survivorship. 22 Therefore, it is imperative to improve the ways in which patients are informed about their fertility and the written decisional support that is provided for fertility preservation.
Patient decision aids (PtDA) can be useful complements in an oncofertility setting, to help inform patients about fertility treatment options and guide decision-making processes. 24 These tools are designed to provide patients with written information about available treatment options and likely treatment outcomes, in order to assist patients in selecting the best treatment option suited to their individual situation and personal values. 25 Studies have shown that PtDAs are effective at reducing decisional conflict and allowing patients to take an active role in their treatment planning, and lead to greater satisfaction with care and improved psychosocial outcomes. 17 The efficacy of PtDAs in female cancer patients of reproductive age, for example, within a breast cancer population in Australia, has been shown to significantly reduce decisional regret. 26 Research had yet to review the effectiveness of PtDAs in assisting fertility preservation decision-making for both male and female patients across all cancer types. Although an environmental scan had been undertaken in previous literature to assess the efficacy of fertility preservation PtDAs, 27 research had yet to systemically assess the peerreviewed literature on effectiveness of these PtDAs, in view of guiding further implementation research. Fertility preservation PtDAs may be a valuable resource to implement into standard clinical practice. 26 Despite this benefit, research indicated that these tools may not be readily available to support fertility preservation decision-making, 28 Figure 1 for inclusion exclusion flowchart).
The literature search was conducted in March 2018 utilising five electronic databases: Medline, EMBASE, PSYCH Info, PubMed, and Web of Science. Search terms were altered for each database to map to specific subheadings (see Table 1 for a summary of all search terms). 
| Quality assessments
The quality and risk of bias of the remaining studies were assessed using the Mixed Methods Appraisal Tool (MMAT). 29 The MMAT assesses quality of either qualitative or quantitative research on the domains of sampling, measurements, completion of data, and bias.
Scores on the MMAT vary from 25% (one criterion met) to 100% (all criteria met). The majority of studies assessed reported sound quality (n = 4 scored 100% 26, [30] [31] [32] ; n = 3 scored 75% 31, 33, 34 ; n = 2 scored 50%). 24, 35 One study's quality score was poor (25%) 36 ; however, this was likely due to the review nature of the study being inadequately appraised by the MMAT, and as such, it was retained for final analysis.
Two studies were considered "grey literature" in the form of conference abstracts and could not be assessed on quality.
37,38
3 | RESULTS
A total of 12 papers, from 11 studies, evaluating nine PtDAs were reviewed (see Table S1 for full study details and extracted data). The studies were published between 2009 and 2018 and originated from six countries. One study utilised mixed-methods design (questionnaires and interviews) 24 while all others were quantitative, utilising FIGURE 1 A PRISMA flowchart for inclusion and exclusion of papers reporting on a fertility preservation patient decision aid tool for cancer patients online or paper-based questionnaires. 24, 26, [30] [31] [32] [35] [36] [37] 39, 40 Study type was categorised according to an efficacy and effectiveness rating tool. 41 One study was developmental, 36 five contained both stages of development and efficacy, 24, 30, 32, 34, 39 five were efficacy or effectiveness studies, 26, 31, 35, 37, 40 and one was an implementation study. 33 
| Characteristics of participants in included studies
Sample sizes ranged from nine to 337 (mean sample size = 64.3) with a total of 772 participants across all studies. In the studies with control arms, there were no significant differences between control and intervention groups on demographic variables such as age and education level.
Ten studies recruited cancer patients, 24, 26, [30] [31] [32] [33] [34] [35] [36] [37] one study recruited survivors, 36 and one recruited parents of cancer patients. 40 A variety of health care professionals involved in the care of cancer patients (including oncologists, gynaecologists, and nurses) were recruited by four studies largely to evaluate acceptability and usability of the PtDAs. 24, 32, 35, 36 One study recruited healthy women within the community, 24, 39 and specifically healthy women with lower education, 24 who were asked to make a hypothetical decision about fertility preservation if they were diagnosed with cancer.
Age of cancer patients and survivors ranged from 18 to 43 years.
Patient populations differed on stage of treatment. Four studies specifically recruited newly diagnosed patients, or patients who had yet to commence any adjuvant therapies. 26, 30, 31, 33 One study recruited patients who had undergone no more than 1 week of treatment. 35 Two studies did not specify length of treatment, rather recruited patients based on time since diagnosis (within 5 y), 32, 34 time since fertility preservation decision (at least 1 y ago), 24 or did not specify any patient criteria. 37 Another, detailing a development study, recruited a combination of patients and survivors who were analysed together as the same group and did not specify a time frame since diagnosis. 36 
| Patient decision aids
The format of PtDAs differed between online (n = 5) 24,30,32,37,39,40 and paper-based booklets (n = 2). 26, 34, 36 One PtDA was integrated within a computerised educational tool. 35 Another PtDAs from an implementation study came in the format of a decision tree. 33 Five of the tools were in English, 26, 32, 34, 35, 37, 40 and there was one each in Portuguese, 36 Dutch, 24, 31, 39 German, 30 and Japanese. 33 The
PtDAs typically consisted of informative sections and interactive sections with values clarification exercises, 24, 26, [30] [31] [32] 34, 39 quizzes to assess patient knowledge, 35 and space for notes or questions. 26, 30, 34 Video testimonials from female cancer survivors who had made decisions about fertility preservation in the past were also included. 32 All the PtDAs were primarily targeted at health care consumers (patients and their families). One PtDA had separate sections developed for patients and clinicians. 35 The majority of PtDAs were solely targeted at female cancer patients (n = 6). 24, 26, [30] [31] [32] [33] [34] 39 Two tools were designed for male patients, 35 ,36 one of which from a study that developed a separate PtDA for both male and female patients. 36 One study analysed a PtDA created for parents of paediatric cancer patients of any gender. 40 Six PtDAs were not specific to any cancer type, 30, 33, [35] [36] [37] 40 one was able to be tailored specifically to several types of cancer, 32 while two specifically targeted breast cancer. 24, 26, 31, 34, 39 The majority of PtDAs were designed to be implemented during treatment planning or prior to chemotherapy or radiation therapy exposure, as this is the most effective period to pursue fertility preservation. Only one tool specifically stated that it was also suitable to be used by cancer survivors following completion of treatment. 32 The International Patient Decision Aid Standards (IPDAS) Collaboration are quality criteria for assessing the development of PtDAs. 25 Three PtDAs were reported to have been developed utilising IPDAS criteria, with full IPDAS scores reported in two studies. 24, 30, 32 The first
PtDA met seven out of seven criteria to be defined as a decision aid, eight out of eight criteria to lower the risk of making a biased decision, and 10 out of 10 criteria for quality development. 32 Eight other criteria were not applicable. The second PtDA was reported to have met 43 out of 48 criteria for development and content. 24 The authors were able to assess an additional PtDA that was locally available using the IPDAS criteria. The PtDA met seven out of seven criteria to be defined as a decision aid, six out of nine criteria to lower the risk of making a biased decision, and 11 out of 12 criteria for quality development (five other criteria not applicable). 26, 34 The remaining studies did not report on IPDAS score, nor was an IPDAS score able to be calcu- . 44 Knowledge about fertility preservation was utilised across 10 studies, with one study utilising the MMIC 26 and others using short knowledge quizzes assessing the patient's understanding of content included in the PtDA. Statistically significant improvements in fertility preservation knowledge pre and post viewing a PtDA in populations of cancer patients were noted in three studies (P = 0.002-0.04). 26, 31, 37 In one sample this knowledge was retained at 6 months. 37 Significant improvements in knowledge were also reported by parents of paediatric cancer patients (P = 0.04) 40 and healthy women (P = <0.001-0.024). 24 Another study found that viewing a PtDA resulted in moderate level fertility preservation knowledge; however, this study did not evaluate knowledge prior to use. 32 Two studies with newly diagnosed female cancer patients reported that a PtDA combined with standard care (a brochure or fertility counselling)
group, compared with standard care alone group, reported commensurate increases in fertility knowledge 31 and no significant group differences. 30, 31 However, those who accessed fertility counselling and a
PtDA did report significantly greater knowledge confidence (P = 0.047). 30 Recently diagnosed male cancer patients reported no 
| Decisional conflict
The decisional conflict scale was utilised across six studies to assess levels of decisional conflict experienced by patients in relation to their fertility preservation. This scale assesses the uncertainty surrounding a decision and the individual's self-perceived effective decision-making.
Scores range from 0 to 100 with scores above 37.5 indicating high decisional conflict. 45 Two studies indicated a statistically significant (P = 0.02) reduction in decisional conflict in newly diagnosed female cancer patients after PtDA use when measured 37 at 6 and 12 months (breast cancer patients only). 26 Similarly, lower decisional conflict was reported in men who viewed a PtDA compared with those who did not (P = 0.0065). 35 There were no significant differences in decisional conflict between a brochure only or counselling only intervention, compared with a PtDA, 30, 31 or between PtDAs with or without a values clarification exercise. 39 Therefore, the merit of PtDAs, or use of values clarification exercises, in significantly reducing decisional conflict compared with other supportive interventions is not reported.
| Satisfaction and acceptability
There was extensive evaluation of satisfaction and acceptability of the utilisation of PtDAs. Several studies reported that patients, clinicians, and parents viewed these tools positively. 26, 32, 34, 36, 40 For example, in one sample, more than 85% of women "agreed" or "strongly" agreed it was useful, attractive, clear, and easy to use; 75% of women felt empowered after using it, and 85% reported they felt ready to discuss fertility with their health care provider. 32 Similarly, a second sample reported 94% of participants rated the PtDA as "very" or "quite"
relevant, and 88% would recommend it to others. 34 A third developmental study reported both patients and clinicians felt the PtDA was easy to read, well organised, and contained relevant information. 36 Two studies reported that the PtDA elicited some negative feelings, with half (53%) of breast cancer survivors reporting use of the PtDA made them "a little" sad, and a third (29%) felt it made them "quite a bit sad or upset." Some women also reported that using the PtDA made them "somewhat" (19%), "a little" (38%), or "quite a bit" (13%) "worried or concerned." The participants reported that these feelings were related to both their understanding of their impacted fertility, and due to remembering a distressing period in their lives. 34 Similarly, a subsample of five women in a second study felt upset or nervous while using the PtDA. Two studies utilised the decisional regret scale to measure regret associated with fertility preservation treatment decisions in newly diagnosed female breast cancer patients, comparing a PtDA to a brochure or consumer guide. 26, 31 This five-item scale assesses aspects associated with decisional regret, such as whether the patient felt that it was the right decision and whether the decision did the patient harm. 46 Both studies reported a trend towards higher decisional regret over time in the intervention and control groups. 26, 31 No significant differences in anticipated regret between groups were reported at baseline, or regret at 6 months
31
; however, significantly lower decisional regret was shown at 12 months (P = 0.031) in the intervention group, compared to a group with standard care. 26 Three studies evaluated the impact of PtDA use on fertility preservation preferences and decision-making values. 26, 31, 32 No significant differences were reported in patient's decision-making values in one survivor sample, 32 or in fertility preservation decisions between the PtDA groups and control groups at the time of diagnosis.
26,31
| Objective 2: current use of fertility preservation PtDAs in clinical care
The authors of the PtDAs were contacted to confirm the availability of the tools for use in clinical care. At the time of search, three PtDAs were available for clinical use, one each in Australia (English), 26, 34 Portugal (Portuguese), 36 and the Netherlands (Dutch). 24, 31, 39 Upon review, one PtDA was no longer available. 24, 31, 39 Three PtDAs are awaiting further evaluation before they are made publicly available. 30, 32, 40 The materials of another one PtDA had been largely incorporated into a new web-based self-help program for men. 35 A further
PtDA was ultimately not implemented into clinical practice as researchers deemed it inappropriate for their health care system given the limitations placed on options for fertility preservation and alternative family planning. 33 It is unclear what stage of development the final PtDA is in. 37 One paper describing an implementation study with a decision tree evaluated fertility preservation outcomes for women. The study reported that 48.6% of patients chose to undergo embryo cryopreservation with a mean of 5.29 embryos cryopreserved per patient and a calculated expected live birth rate of 0.66. An additional 11.4% of patients opted for oocyte cryopreservation but were referred elsewhere and as such follow-up data was not available. Overall, these results are consistent with those reported in the Cochrane review of decision aids, in that PtDAs assist patients to feel more comfortable with their health treatment choices and compared with usual care, improve individual's perception of involvement in decision-making via increased knowledge, and lower decisional conflict and decisional regret. 43 Similarly, when IPDAS criteria was available, fertility preservation PtDA tools reported within this review were reported to be of suitable quality. 25 It is important to consider that a normative part of the decisionmaking process for newly diagnosed cancer patients may include heightened negative emotion that should not be interpreted as a negative impact of utilising a PtDA tool. Although lower decisional conflict has been associated with less fretting, nervousness, and decreased tendency to postpone decision-making, 46 higher decisional conflict in newly diagnosed cancer patients may indicate that patients are actively engaged with difficult treatment decision-making. Conversely, heightened decisional conflict in cancer survivors may be more reflective of uncertainty surrounding the effective decision-making in the past. Thus, both the level of decisional conflict and patient status are important factors for clinicians to consider in best supporting cancer patients and survivors with their fertility. Similarly, negative feelings associated with PtDA use may be a result of increased awareness while decision-making needs are being met and is not necessarily a deterrent from utilising these tools. Indeed, research indicates that heightened anxiety is common for patients adjusting to the news of infertility and making difficult decisions surrounding fertility preservation. 47 At the time of this review, the current availability of these PtDA tools for clinical use is limited. Currently, only two of the tools reported within this review are likely available for clinical use, and a further tool's content has since been integrated into a web page.
Additionally, one implementation study was available, which reported on the fertility preservation outcomes after utilisation of the PtDA.
This low uptake may be due to the stage of development of most tools, with the majority of studies published within the last 5 years, and thus, most PtDAs are likely still in development or undergoing evaluation. However, it does highlight the potential benefit of future research in implementing and disseminating these peer-reviewed, evidence-based PtDAs to assist future clinical use. This is a growing area of interest, with literature indicating that six other tools may be made available upon completion of development and evaluation in the future, three of which are reported within these results, 29, 31, 39 and the remaining outlined in protocols. 26, 37, 49 Therefore, there may be a greater body of evidence to support the implementation of these tools into clinical practice in the near future.
| Study limitations
The findings from this review may be limited in its generalisability to a wider population of cancer patients due to the small sample sizes 
| Clinical implications
To the best of our knowledge, this is the first systematic review that investigates the effectiveness of fertility preservation PtDAs targeted at cancer patients. Given that limited written information regarding fertility is a prominent barrier for cancer patients of reproductive age, the implementation of fertility preservation PtDAs may act as a complement to current fertility care, by assisting patients in becoming more informed and able to make fertility preservation decisions appropriate to their personal situation. However, it is important to note that irrespective of the effectiveness of such tools, their use cannot replace verbal communication with health care professionals. Therefore, it is imperative that clinicians, including reproductive, oncology, and haematology specialists, are aware of current treatment options available and best practice models of care. PtDAs with clinician-targeted sections may also be beneficial in assisting oncology clinicians to discuss fertility preservation options with patients in a timely manner and refer on to specialist care.
With reasonable effectiveness and low levels of current use in clinical care, future research needs to consider the implementation of these resources into standard care. The vast majority of tools reviewed in this study are targeted at female cancer patients. This is likely because there are currently a number of fertility preservation options available for women while sperm banking remains the sole established method for males. Moreover, the procedures involved for women are generally more invasive, expensive, and, historically, may have required cancer treatment to be delayed. 47 However, results from the studies reviewed suggest that male patients may benefit similarly from access to PtDAs and they are therefore a useful complement to clinical practice regardless of patient gender, or complexity of decisional process in assisting patient satisfaction with fertility care.
Resources to support fertility decision-making in survivorship are currently limited with only one tool suitable to be implemented at this time point. 32 Given the current challenges with timely information provision and referrals to fertility preservation, some survivors may not have had the opportunity to discuss fertility prior to treatment or, for a number of reasons, may have declined fertility preservation at the time. Moreover, cancer survivors report ongoing concerns regarding the uncertainty of their fertility status following treatment. 48 It is important that survivors receive adequate support postoncological treatment to assess their fertility and options for family building. The provision of PtDAs for assessing fertility and alternative family planning options in survivorship can provide an opportunity to meet these ongoing needs and should be an area of focus for future research. Longitudinal research comparing patient perceptions of decision-making at the time of diagnosis with these same views in survivorship, in the context of fertility and ovarian reserve (females) and testicular function (males), may be particularly beneficial in understanding the long-term decision-making outcomes and offering insight into long-term models of support.
Another area of consideration is the age appropriateness of PtDAs for patients across the reproductive age range. Adolescent and young adults are at a key stage in their development and present with unique psychosocial concerns and support needs. They may have differing health literacy 49 and decision-making processes 50 to their adult counterparts. While many patients in this age group are not at the point of active family planning, fertility is still a key concern for most patients. 50 Because of the distinctive needs of paediatric patients, it is difficult to extrapolate the results from the adult studies in this review into this population without further evaluation by younger participants. Currently, only one PtDA targeting paediatric cancer patients exists, 40 designed to be administered to parents. Given paediatric and adolescents' potential differing cognitive development and health literacy understanding, age appropriate adaptations will be required for paediatric and AYA patients, which include changes in language, length of PtDA, and the integration of psychosocial support.
The lack of paediatric resources may be attributed to minimal fertility preservation options available to prepubertal paediatric cancer patients and other barriers to paediatric fertility preservation including ethical issues surrounding proxy decision-making. 51 However, with increasing clinical recommendations for management of fertility preservation in prepubertal patients, this is an area worthy of further consideration.
In considering future dissemination of current PtDAs, it is important to consider equity of access. The tools included in this review came in five languages (English, Dutch, German, Portuguese, and Japanese), and with the exception of English, only one tool was available for each language. In order to be inclusive, the tools need to be available in a larger variety of languages to meet the needs of ethnically diverse patients within the health settings in which the tools have been developed. Translation of existing tools that have undergone prior evaluation in a culturally sensitive manner will assist migrant patients to better access and utilise local health services alongside cultural majority patients. Similar consideration needs to be given to patients with lower health literacy, and given that this factor is associated with lower knowledge about health care options, higher uncertainty, and regret surrounding decision making, 52 how current tools can be adapted to suit literacy level is worthy of consideration.
| CONCLUSION
In conclusion, 12 papers, detailing 11 studies and evaluating nine fertility preservation PtDAs, report that these tools are positively viewed by patients and clinicians, improve knowledge about fertility preservation, and may lower decisional conflict and regret. Given the recency in current literature there are limited PtDAs currently available for clinical use and limited implementation studies. As such, further research should look into implementation with female and male adult and paediatric patients at both the time of diagnosis and survivorship.
Optimising information delivery and tailoring for subgroups of cancer patients, including lower health literacy and other spoken languages, is also worthy of consideration. Overall PtDAs may serve as a valuable complement to current fertility care practices, in ensuring needs for high-quality information and support that are met alongside clinical consultations.
